The CIRCULATE trial: circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II evaluation (AIO-KRK-0217)
G Folprecht, A Reinacher-Schick, J Weitz… - Clinical Colorectal …, 2022 - Elsevier
Background Guidance regarding adjuvant treatment decisions in stage II colorectal cancer
(CRC) remains uncertain due to lack of predictive clinical or molecular markers. Recently …
(CRC) remains uncertain due to lack of predictive clinical or molecular markers. Recently …
[HTML][HTML] Integrating cycled enzymatic DNA amplification and surface-enhanced Raman scattering for sensitive detection of circulating tumor DNA
X Miao, Q Fang, X Xiao, S Liu, R Wu, J Yan… - Frontiers in Molecular …, 2021 - frontiersin.org
Circulating tumor DNA (ctDNA) represents an emerging biomarker of liquid biopsies for the
development of precision cancer diagnostics and therapeutics. However, sensitive detection …
development of precision cancer diagnostics and therapeutics. However, sensitive detection …
[HTML][HTML] Nanotechnology for Precision Cancer Therapy: Advances in Gene Therapy, Immunotherapy, and 3D Bioprinting
Cancer is a significant health hazard of the 21st century, and Global Observatory of Cancer
(GLOBOCAN) predicts increasing cancer incidence in the coming years. Nanotechnology …
(GLOBOCAN) predicts increasing cancer incidence in the coming years. Nanotechnology …
Kidney Cancer Study Puts Circulating Tumor DNA Assay to Test
P Abbosh - clpmag.com
Natera, San Carlos, Calif, a genetic testing and cell-free DNA analysis company, has
partnered with Fox Chase Cancer Center to assess the company's Signatera customized …
partnered with Fox Chase Cancer Center to assess the company's Signatera customized …
Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
C Harrison - cancertherapyadvisor.com
The ctDNA testing method demonstrated 93% sensitivity for relapse detection at variant
allele frequencies of 0.1% and above, the authors reported, with no false positives in the …
allele frequencies of 0.1% and above, the authors reported, with no false positives in the …
[引用][C] A phase II randomized study of tiragolumab plus atezolizumab versus atezolizumab in the treatment of stage II melanoma patients who are ctDNA-positive …
G Ansstas
[引用][C] Kidney Cancer Study Puts Circulating Tumor DNA Assay to Test Published on September 28, 2018
P Abbosh